Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT03019003
Title A Phase IB/II Study With Azacitidine, Durvalumab, and Tremelimumab in Recurrent and/or Metastatic Head and Neck Cancer Patients
Recruitment Active, not recruiting
Gender both
Phase Phase Ib/II
Variant Requirements No
Sponsors Massachusetts General Hospital
Indications

head and neck squamous cell carcinoma

Therapies

Azacitidine + Durvalumab + Tremelimumab

Age Groups: adult | senior
Covered Countries USA


No variant requirements are available.